# DANYELZA

NDC: 73042-201
Generic name: Naxitamab
Labeler / Manufacturer: Y-mAbs Therapeutics, Inc.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION
Routes: INTRAVENOUS
Marketing started: 20201125

FDA application: BLA761171

## Active ingredients

- NAXITAMAB: 40 mg/10mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"73042-201"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=73042-201
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=29a80c6b-8bad-4650-8c7f-f18490c868ec